# Plasma Fractionation Market: Growing at a CAGR of 7.1%
Plasma Fractionation Market Size, Share & COVID-19 Impact Analysis, By Product (Albumin, Immunoglobulin (Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)), Coagulation Factors (Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others), Protease Inhibitors, Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, Others), By End-user (Hospitals & Clinics, Clinical Research Laboratories, Others), and Regional Forecast, 2022-2029

Plasma fractionation is the process of separating blood plasma into its components. The different components of plasma can be used to treat a variety of diseases, including haemophilia, immunodeficiency, and burns.

The plasma fractionation market is expected to grow at a CAGR of 7.1% from 2022 to 2029. This growth is being driven by the increasing demand for plasma-derived products, the ageing population, and the rising prevalence of chronic diseases.

**Get More Insights:** https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614

**Segmentation**

The plasma fractionation market is segmented by product, application, and region.

The product segment is further segmented into albumin, immunoglobulins, coagulation factors, and other plasma fractions. Albumin is the largest segment, and it is used to treat a variety of conditions, such as hypovolemia, shock, and burns. Immunoglobulins are used to treat immunodeficiency disorders, such as primary immunodeficiency and HIV/AIDS. Coagulation factors are used to treat haemophilia and other bleeding disorders. Other plasma fractions include cryoprecipitate, alpha-1 antitrypsin, and fibrinogen.

The application segment is further segmented into therapeutic and diagnostic. Therapeutic is the largest segment, and it includes applications such as haemophilia treatment and immune globulin replacement therapy. Diagnostic is the smallest segment, and it includes applications such as von Willebrand factor assays and factor VIII assays.

The region segment is further segmented into North America, Europe, Asia-Pacific, and Latin America. North America is the largest market for plasma fractionation, followed by Europe and Asia-Pacific. Latin America is the smallest market, but it is growing at the fastest pace.

**Key Players**

The key players in the plasma fractionation market include Grifols, Kedrion, CSL Behring, Octapharma, and Biotest. These companies are investing in research and development to develop new and innovative plasma fractionation technologies.

**Trends**

The plasma fractionation market is expected to continue to grow in the coming years, driven by the following trends:
Increasing demand for plasma-derived products: The demand for plasma-derived products is increasing due to the rising prevalence of chronic diseases, such as haemophilia and immunodeficiency.

Ageing population: The ageing population is a major driver of the plasma fractionation market, as older adults are more likely to experience age-related diseases that require plasma-derived products.
Technological advancements: There have been significant technological advancements in plasma fractionation in recent years. These advancements have made it possible to produce plasma-derived products that are more pure and effective.

**Conclusion**

The plasma fractionation market is a growing market, and it is expected to continue to grow in the coming years. The market is being driven by the increasing demand for plasma-derived products, the aging population, and technological advancements.